What happened in the stock market today

As the Brexit waiting game continues, company news today included the shock departure of a FTSE 100 chief executive.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 and the pound started this morning modestly positive and maintained it for much of the day. The Brexit waiting game goes on. Commons Speaker John Bercow refused the government’s call to hold another vote on the Prime Minister’s Brexit deal today.

Blue-chip boss departure

In today’s company news, the healthcare sector was prominent. Pharma giants AstraZeneca and GlaxoSmithKline both had updates, albeit with no big impact on their share prices.

AZN announced its Farxiga treatment has been approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes. GSK revealed it’s agreed to divest its rabies and tick-borne encephalitis vaccines to Danish firm Bavarian Nordic. This for an upfront payment of €301m (£259m), with milestone payments taking the total consideration up to €955m (£822m).

Meanwhile, Circassia Pharmaceuticals announced the US launch of Duaklir for the treatment of chronic obstructive pulmonary disease. The company described the launch as “a major strategic milestone.” The market shrugged, and sent the small-cap firm’s shares a few percent lower.

Returning to the FTSE 100, healthcare firm Smith & Nephew saw a big move in its shares. Down. As much as 10% at one point. This followed a shock announcement that chief executive Namal Nawana is stepping down after less than 18 months in the job.

The company said Nawana will leave on 31 October, “by mutual agreement … to pursue other opportunities outside of the UK.” Behind this are reports the company couldn’t, or wouldn’t, meet his demands for higher pay, in line with the bosses of US medical device-makers.

Other big FTSE 100 fallers

Just Eat and Prudential spent most of the day vying with Smith & Nephew for the bottom slot on the FTSE 100 fallers board. Just Eat’s drop follows the release of its Q3 results in which key metrics were below City expectations. While the company reconfirmed its full-year revenue and earnings guidance, analysts expect the consensus to move down to the lower end of the range.

My Foolish colleague Alan Oscroft doesn’t downplay the potential of the food ordering platform and delivery business. However, he has some wise words on early movers with shares on super high valuations.

Insurer Prudential’s fall was triggered by today’s formal demerger of its M&G UK asset management business. An investor who owned 1,000 Prudential shares on Friday now also owns 1,000 shares in the separate M&G company. After reviewing today’s developments, fellow Fool Roland Head concluded he’d be happy to own either – or both stocks.

Mid-cap movers

In the FTSE 250, Capital & Counties Properties, the owner of Covent Garden and Earls Court, was prominent among the risers. This came after confirmation a consortium led by Candy Ventures is in the early stages of considering a possible cash offer for the company.

At the other end of the mid-cap movers board, troubled technology firm Micro Focus International was rooted to the bottom for most of the day. A Bloomberg report that Canadian group OpenText was weighing a bid for the company was scotched by OpenText in a statement this morning.

Small-cap shooting star

Finally, the biggest riser on the London market was AIM-listed Watchstone (formerly Quindell). The company’s long-running battle over £50m with Australian firm Slater & Gordon has been settled. Watchstone’s getting £39m from the pot and S&G £11m.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca, GlaxoSmithKline, Micro Focus, and Prudential. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two white male workmen working on site at an oil rig
Investing Articles

As oil prices soar, is it time to buy Shell shares?

Christopher Ruane weighs some pros and cons of adding Shell shares to his ISA -- and explains why the oil…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

How much do you need in an ISA for £6,751 passive income a year in 2046?

Let's say an investor wanted a passive income in 20 years' time. How much cash would need be built up…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Why isn’t the IAG share price crashing?

Harvey Jones expected the IAG share price to take an absolute beating during current Middle East hostilities. So why is…

Read more »

piggy bank, searching with binoculars
Growth Shares

1 UK share I’d consider buying and 1 I’d run away from on this market dip

In light of the recent stock market dip, Jon Smith outlines the various potential outcomes for a couple of different…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

AI may look like a bubble. But what about Rolls-Royce shares?

Bubble talk has been centred on some AI stocks lately. But Christopher Ruane sees risks to Rolls-Royce shares in the…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Will the BAE Systems share price soar 13% by this time next year?

BAE Systems' share price continues to surge as the Middle East crisis worsens. Royston Wild asks if the FTSE 100…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Is this a once-in-a-decade chance to bag a 9.9% yield from Taylor Wimpey shares?

Taylor Wimpey shares have been hit by a volatile share price and cuts to the dividend. Harvey Jones holds the…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Way up – or way down? This FTSE 250 share could go either way

Can this FTSE 250 share turn its fortunes around? Or has its day passed? Our writer looks at both sides…

Read more »